<DOC>
	<DOC>NCT00909961</DOC>
	<brief_summary>This study will evaluate the effects of zoledronic acid 5 mg infusion on BMD and biochemical markers of bone in post-menopausal osteoporotic patients aged between 50-65.</brief_summary>
	<brief_title>A Trial Evaluating the Effects of Zoledronic Acid 5 mg Infusion on Bone Mineral Density (BMD) in Postmenopausal Osteoporosis (PMO) Patients Between the Ages of 50 and 65 Years</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Postmenopausal osteoporosis Patients who has a low bone mineral density at hip or vertebral Patients who has an osteoporotic fracture at hip or vertebra Hypersensitivity either to the active substance or to any of the excipients or to any biphosphonates. Known metabolic bone disease excluding osteoporosis. Serious systemic disorder treated with drugs interfering with bone metabolism. Significant liver or renal failure Pathologic fracture in the examined body area or elsewhere. Previous antiosteoporotic treatment within 12 months or less prior to the recruitment. Patients with hypocalcaemia Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>Bone Mineral Density</keyword>
	<keyword>Biomarkers</keyword>
</DOC>